New theranostic approach reduces tumor volume and increases survival in NET study

December 16, 2020

Reston, Virginia--A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as two fractionated doses, as opposed to one.

Neuroendocrine tumors typically are diagnosed with 68Ga-DOTA-octreotate and treated with 177Lu-LuTATE peptide receptor radionuclide therapy. However, using two different chemical elements (Ga and Lu) can lead to inconsistent tissue biodistribution, as they do not have the same binding and internalizations interactions. "Ideally, a chemically identical 'imaging-therapeutic' pair of radionuclides bound to the same targeting agent should be used for diagnosis and treatment," said Paul S. Donnelly, BSc(Hons), PhD, professor in the School of Chemistry at the University of Melbourne in Melbourne, Victoria, Australia.

In the study, researchers utilized a preclinical mouse model to explore the chemically identical radionuclide pair 64Cu-CuSarTate and 67Cu-CuSarTate. To assess the ability of 64Cu-CuSarTate to positively identify tumors, PET imaging occurred at one hour and four hours after injection of the radiotracer. On completion of the four-hour imaging, mice were euthanized and biodistribution studies were performed.

Multiple therapy experiments were also performed to evaluate the efficacy of 67Cu-CuSarTate. In the first, mice were injected with five MBq of 177Lu-LuTATE, five MBq of 67Cu-CuSarTate or saline and monitored for tumor growth. In the second experiment, mice were injected with a total of 30 MBq of 177Lu-LuTATE, 67Cu-CuSarTate or saline either as a single intravenous injection or as two 15 MBq fractions, two weeks apart; tumor growth was then monitored.

64Cu-CuSarTate PET images acquired at both one hour and four hours post-injection revealed very high tumor uptake and excellent tumor-to-background ratios. The high tumor uptake was confirmed with the ex vivo biodistribution analysis. Tumor growth was inhibited by 75 percent with 67Cu-CuSarTate treatment and by 89 percent with 177Lu-LuTATE, and survival was extended from 12 days in the control group to 21 days following treatment with both therapies. Treatment of tumors with two fractions of either 177Lu-LuTATE or 67Cu-CuSarTate significantly improved survival when compared to delivery as a single fraction. Equivalent efficacy was observed between the two therapies following treatment on both the single and fractionated schedules.

"Copper radionuclides are beneficial for several reasons," said Rodney J. Hicks, MBBS, MD, FRACP, FAHMS, professor in the Sir Peter MacCallum department of oncology at the University of Melbourne, in Melbourne, Victoria, Australia. "The strong binding of copper within the tumor allows for increased detection of disease, which can serve to limit radiation exposure to normal tissues during therapy. The ability to image at multiple time points with 64Cu-CuSarTate supports prospective dosimetry for therapeutic treatment planning with 67Cu-CuSarTATE, which could potentially offer shorter cycling of treatment, particularly for more aggressively growing tumors."

In terms of potential translation of the copper-64/67 theranostic pair to clinical studies, it is pertinent that copper-64 is produced in a cyclotron. The longer half-life of 64Cu-CuSarTATE as compared to 68Ga-DOTA-octreotate means that the tracer can be easily produced under good manufacturing practice conditions and transported regionally. 67Cu-CuSarTATE can be produced with linear-accelerators in high specific activity and radionuclide purity, so it is not reliant on nuclear reactors.

"Looking to the future of molecular imaging and nuclear medicine, the chemistry and general concepts presented in this study could be expanded to other peptides that target different receptors, as well as antibodies and engineered antibody fragments. This offers the potential to provide diagnostic imaging using copper-64 to plan individualized treatments with copper-67 agents for a wide range of cancer patients," noted Donnelly.
This study was made available online in May 2020 ahead of final publication in print in December 2020.

The authors of "Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE is Highly Efficacious Against a Somatostatin Positive Neuroendocrine Tumor Model," include Carleen Cullinane, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia, and Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Charmaine M. Jeffrey, Ellen M. van Dam and Matthew J. Harris, Clarity Pharmaceuticals Ltd., Eveleigh, New South Wales, Australia; Peter D. Roselt, Price Jackson and David Binns, Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Susan Jackson and Jessica van Zuylekom, Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Kevin Kuan, Molecular Imaging and Therapy Research Unit, SAHMRI, Adelaide, South Australia, Australia; Rodney J. Hicks, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia, and Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and Paul S. Donnelly, School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, Victoria, Australia.

Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or

About the Society of Nuclear Medicine and Molecular Imaging

The Journal of Nuclear Medicine (JNM) is the world's leading nuclear medicine, molecular imaging and theranostics journal, accessed close to 10 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at

JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging--precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit

Society of Nuclear Medicine and Molecular Imaging

Related Tumor Growth Articles from Brightsurf:

New insights into colorectal cancer: Growth factor R-spondin suppresses tumor growth
R-spondin, which enhances the growth of healthy cells in the gut, suppresses the growth of intestinal adenoma cells, thus reducing the formation of intestinal tumors.

Finding a way to STING tumor growth
The immune protein STING has long been noted for helping protect against viruses and tumors by signaling a well-known immune molecule.

Flipping a metabolic switch to slow tumor growth
The enzyme serine palmitoyl-transferase can be used as a metabolically responsive ''switch'' that decreases tumor growth, according to a new study by a team of San Diego scientists, who published their findings Aug.

Researchers determine how a specific protein regulates tumor growth
Immune checkpoints are surface proteins that cancer cells use to evade immune response.

Fibroblasts involved in healing spur tumor growth in cancer
The connective tissue cells known as fibroblasts are vitally important for our recovery from injury.

Glutamine-blocking drug slows tumor growth and strengthens anti-tumor response
A compound developed by Johns Hopkins researchers that blocks glutamine metabolism can slow tumor growth, alter the tumor microenvironment and promote the production of durable and highly active anti-tumor T cells.

Neurons promote growth of brain tumor cells
In a current paper published in the journal 'Nature', Heidelberg-based researchers and physicians describe how neurons in the brain establish contact with aggressive glioblastomas and thus promote tumor growth / New tumor activation mechanism provides starting points for clinical trials.

Hole-forming protein may suppress tumor growth
A gene called gasdermin E, which is downregulated in many cancers, aids cells in dying in an unexpected way, and may also suppress tumor growth.

New formula better predicts speed of tumor growth in 12 cancers
University at Buffalo researchers have developed a new method to more accurately predict tumor growth rates, a crucial statistic used to schedule screenings and set dosing regimens in cancer treatment.

Enlarged prostate could actually be stopping tumor growth, simulations show
Computer simulations show for the first time that when a patient has history of an enlarged prostate, tumors in the prostate barely grow at all.

Read More: Tumor Growth News and Tumor Growth Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to